Elevation Oncology Stock Insider Trading

Healthcare > Biotechnology

Buy ELEV

*Your capital is at risk

$0.365

+0 (+0%)

At Close: Oct 22, 2025

Elevation Oncology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -98.01. In total, the insiders bought 543.5K and sold 3.3M ELEV shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-98.01
● Buy	543.5K shares
● Sell	3.3M shares
29% Buy Activity Weak Positive Correlation
Sell Signal Medium Confidence Jul 23, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -98.01. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 05, 2025 Buy	Stock Option (Right to Buy) A-Award	Carruthers R Michael Director	Director	35 000 Value: $10.7K
Jun 05, 2025 Buy	Stock Option (Right to Buy) A-Award	Sandler Alan B. Director	Director	35 000 Value: $10.7K
Jun 05, 2025 Buy	Stock Option (Right to Buy) A-Award	Mootz Darcy Director	Director	35 000 Value: $10.7K
Jun 05, 2025 Buy	Stock Option (Right to Buy) A-Award	Elms Steve Director	Director	35 000 Value: $10.7K
Jun 05, 2025 Buy	Stock Option (Right to Buy) A-Award	Clackson Timothy P Director	Director	35 000 Value: $10.7K
Jun 05, 2025 Buy	Stock Option (Right to Buy) A-Award	Cherrington Julie M Director	Director	35 000 Value: $10.7K
Jun 05, 2025 Buy	Stock Option (Right to Buy) A-Award	Carruthers R Michael Director	Director	35 000 Value: $10.7K
May 15, 2025 Buy	Restricted Stock Unit M-Exempt	Furlong Tammy Chief Financial Officer	C-Suite Officer	2 343 Value: $702
May 15, 2025 Buy	Common Stock M-Exempt	Furlong Tammy Chief Financial Officer	C-Suite Officer	2 643 Value: $792
May 15, 2025 Sell	Common Stock F-InKind	Furlong Tammy Chief Financial Officer	C-Suite Officer	784 Value: $235
May 15, 2025 Buy	Restricted Stock Unit M-Exempt	Furlong Tammy Chief Financial Officer	C-Suite Officer	300 Value: $90
May 15, 2025 Buy	Common Stock M-Exempt	Ferra Joseph J Jr Chief Executive Officer	CEO / President	6 250 Value: $2K
May 15, 2025 Sell	Common Stock F-InKind	Ferra Joseph J Jr Chief Executive Officer	CEO / President	2 303 Value: $690
May 15, 2025 Buy	Restricted Stock Unit M-Exempt	Ferra Joseph J Jr Chief Executive Officer	CEO / President	6 250 Value: $2K
May 15, 2025 Buy	Restricted Stock Unit M-Exempt	Furlong Tammy Chief Financial Officer	C-Suite Officer	2 343 Value: $702
May 15, 2025 Buy	Common Stock M-Exempt	Furlong Tammy Chief Financial Officer	C-Suite Officer	2 643 Value: $792
May 15, 2025 Sell	Common Stock F-InKind	Furlong Tammy Chief Financial Officer	C-Suite Officer	784 Value: $235
May 15, 2025 Buy	Restricted Stock Unit M-Exempt	Furlong Tammy Chief Financial Officer	C-Suite Officer	300 Value: $90
May 15, 2025 Buy	Common Stock M-Exempt	Ferra Joseph J Jr Chief Executive Officer	CEO / President	6 250 Value: $2K
May 15, 2025 Sell	Common Stock F-InKind	Ferra Joseph J Jr Chief Executive Officer	CEO / President	2 303 Value: $690
May 15, 2025 Buy	Restricted Stock Unit M-Exempt	Ferra Joseph J Jr Chief Executive Officer	CEO / President	6 250 Value: $2K
Mar 16, 2025 Buy	Common Stock M-Exempt	Ferra Joseph J Jr Chief Executive Officer	CEO / President	12 562 Value: $5K
Mar 16, 2025 Sell	Common Stock F-InKind	Ferra Joseph J Jr Chief Executive Officer	CEO / President	4 628 Value: $2K
Mar 16, 2025 Buy	Restricted Stock Unit M-Exempt	Ferra Joseph J Jr Chief Executive Officer	CEO / President	12 562 Value: $5K
Mar 16, 2025 Buy	Common Stock M-Exempt	Ferra Joseph J Jr Chief Executive Officer	CEO / President	12 562 Value: $5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ELEVATION ONCOLOGY, INC.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is bas...

Read Full Profile Here